Until recently double digit sales growth was a given for this stock. Together with the lack of debt and blue sky appeal of possible first line use it has been a compelling buy. At $17 SP a PE about 18.5 is great value for a growth stock with this profile in the health biotech sector.
Unfortunately we have seen a significant decline in sales growth due to a new therapy, I would like to see firm evidence that dose sales growth has improved. Some monthly sales data would be nice. Positive trials data is really needed to move things along on this front.
Fat lady hasn't finished her Aria just yet on the trials front, I'm hoping for a grand finale at ASCO and encore in VESPRO! Hoping there will at least be some subgroups that benefit. Then comes the marketing.
Ann: Trading Halt, page-61
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.020(12.5%) |
Mkt cap ! $76.40M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.5¢ | 17.5¢ | $228.6K | 1.270M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 470379 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 497664 | 7 |
View Market Depth
| Last trade - 11.22am 15/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |